Evommune, Inc.
EVMN
$24.09
-$0.94-3.76%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.00M | 13.00M | 3.00M | 3.00M | 7.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.00M | 13.00M | 3.00M | 3.00M | 7.00M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 13.00M | 13.00M | 3.00M | 3.00M | 7.00M |
| SG&A Expenses | 20.03M | 14.34M | 13.88M | 13.63M | 12.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 94.07M | 85.81M | 79.00M | 84.29M | 77.01M |
| Operating Income | -81.07M | -72.81M | -76.00M | -81.29M | -70.01M |
| Income Before Tax | -68.87M | -61.32M | -64.76M | -78.58M | -66.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -68.87 | -61.32 | -64.76 | -78.58 | -66.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.87M | -61.32M | -64.76M | -78.58M | -66.81M |
| EBIT | -81.07M | -72.81M | -76.00M | -81.29M | -70.01M |
| EBITDA | -79.68M | -71.39M | -74.55M | -79.90M | -68.73M |
| EPS Basic | -27.79 | -40.91 | -43.30 | -52.58 | -44.99 |
| Normalized Basic EPS | -17.37 | -24.95 | -26.45 | -32.25 | -27.51 |
| EPS Diluted | -27.79 | -40.91 | -43.30 | -52.58 | -44.99 |
| Normalized Diluted EPS | -17.37 | -24.95 | -26.45 | -32.25 | -27.51 |
| Average Basic Shares Outstanding | 24.40M | 6.15M | 6.12M | 6.10M | 6.03M |
| Average Diluted Shares Outstanding | 24.40M | 6.15M | 6.12M | 6.10M | 6.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |